Terms: = Skin cancer AND PR, PGR, progesterone receptor
1150 results:
1. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
[TBL] [Abstract] [Full Text] [Related]
2. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
[TBL] [Abstract] [Full Text] [Related]
3. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract] [Full Text] [Related]
4. Breast cryoablation for the palliative treatment of indolent subtype of multicentric triple-negative breast cancer.
Huang ML; Lane DL; Bomar H; Kuerer H
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38627044
[TBL] [Abstract] [Full Text] [Related]
5. Case report: A case of Paget disease outside the axillary breast.
Zhou Z; Zhou B; Wu X; Wei W
Medicine (Baltimore); 2024 Mar; 103(13):e37541. PubMed ID: 38552095
[TBL] [Abstract] [Full Text] [Related]
6. Tailoring Radiation Therapy for Patients With Limited Cutaneous T Cell Lymphoma: Preliminary Clinical Experience With Subtotal skin Electron Therapy.
Laughlin BS; Zaniletti I; Foster MG; Lucido J; Mangold AR; Rosenthal AC; VAN DER Walt C; Breen W; Lester S; Hoppe B; Petersen J; Armstrong MD; Bogan A; Rule WG
Anticancer Res; 2024 Apr; 44(4):1491-1497. PubMed ID: 38537978
[TBL] [Abstract] [Full Text] [Related]
7. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE; Roszik J; Ahmed J; Barretto CMN; Nardo M; Campbell E; Johnson AM; Piha-Paul SA; Oliva ICG; Weathers SP; Cabanillas M; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer; 2024 Mar; 23(1):64. PubMed ID: 38532456
[TBL] [Abstract] [Full Text] [Related]
8. [The exposure routes of micro- and nanoplastics and their potential toxic effects on human health].
Sawicka D; Chojnacka-Puchta L; Zapór L; Miranowicz-Dzierżawska K; Skowroń J
Med Pr; 2024 Mar; 75(1):81-96. PubMed ID: 38523503
[TBL] [Abstract] [Full Text] [Related]
9. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
10. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P; Iannotti N; Cho DC; Kirkwood JM; Villaruz LC; Gibney GT; Hodi FS; Mettu NB; Jones M; Bowman J; Smith M; Lakshminarayanan M; O'Day S
Cancer Res Commun; 2023 Dec; 3(12):2572-2584. PubMed ID: 38115208
[TBL] [Abstract] [Full Text] [Related]
11. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
12. Immunohistochemical and Molecular Characteristics of Anogenital Papillary Hidradenomas.
Karpathiou G; Sim A; Picot T; Mekhzoumi K; Chauleur C; Péoc'h M
Am J Dermatopathol; 2024 Feb; 46(2):79-82. PubMed ID: 38055985
[TBL] [Abstract] [Full Text] [Related]
13. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
Rangel MMM; Linhares LCM; de Oliveira KD; Suzuki DOH; Maglietti FH; de Nardi AB
Sci Rep; 2023 Nov; 13(1):21078. PubMed ID: 38030630
[TBL] [Abstract] [Full Text] [Related]
15. EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia.
Patel SA; Hassan MK; Naik M; Mohapatra N; Balan P; Korrapati PS; Dixit M
Br J Cancer; 2024 Feb; 130(2):184-200. PubMed ID: 38012382
[TBL] [Abstract] [Full Text] [Related]
16. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner A; Versluis JM; Wallace R; Allayous C; Brown LJ; Trojaniello C; Gerard CL; Jansen YJ; Bhave P; Neyns B; Haydon A; Michielin O; Mangana J; Klein O; Shoushtari AN; Warner AB; Ascierto PA; McQuade JL; Carlino MS; Zimmer L; Lebbe C; Johnson DB; Sandhu S; Atkinson V; Blank CU; Lo SN; Long GV; Menzies AM
Eur J Cancer; 2024 Jan; 196():113441. PubMed ID: 37988842
[TBL] [Abstract] [Full Text] [Related]
17. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Patel SP; Othus M; Chae YK; Dennis MJ; Gordon S; Mutch D; Samlowski W; Robinson WRR; Sharon E; Ryan C; Lopez G; Plets M; Blanke C; Kurzrock R
Clin Cancer Res; 2024 Jan; 30(1):33-38. PubMed ID: 37882676
[TBL] [Abstract] [Full Text] [Related]
18. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract] [Full Text] [Related]
19. A case report and literature review on a rare subtype of triple-negative breast cancer in children.
Shi L; Zhang Y; Wu J; Li J; Zhu J; Xu Y; Li N; Li Q; Zhang W
BMC Pediatr; 2023 Sep; 23(1):494. PubMed ID: 37773118
[TBL] [Abstract] [Full Text] [Related]
20. receptor conversion and survival in breast cancer liver metastases.
Sundén M; Norgren S; Lundqvist R; Andersson A; Sund M; Hemmingsson O
Breast Cancer Res; 2023 Sep; 25(1):105. PubMed ID: 37705026
[TBL] [Abstract] [Full Text] [Related]
[Next]
